NASDAQ:CDMO - Avid Bioservices Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$5.57 -0.17 (-2.96 %)
(As of 08/16/2018 02:11 AM ET)
Previous Close$5.74
Today's Range$5.47 - $5.75
52-Week Range$2.24 - $6.57
Volume430,496 shs
Average Volume497,818 shs
Market Capitalization$319.70 million
P/E Ratio-11.12
Dividend YieldN/A
Beta2.19
Avid Bioservices logoAvid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California.

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Debt-to-Equity RatioN/A
Current Ratio1.79
Quick Ratio1.37

Price-To-Earnings

Trailing P/E Ratio-11.12
Forward P/E Ratio-27.85
P/E GrowthN/A

Sales & Book Value

Annual Sales$53.62 million
Price / Sales5.82
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book5.57

Profitability

EPS (Most Recent Fiscal Year)($0.50)
Net Income$-21,810,000.00
Net Margins-40.68%
Return on Equity-58.67%
Return on Assets-31.70%

Miscellaneous

Employees186
Outstanding Shares55,990,000
Market Cap$319.70 million

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?

Avid Bioservices announced a dividend on Wednesday, March 7th. Stockholders of record on Monday, March 19th will be paid a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date is Friday, March 16th. View Avid Bioservices' Dividend History.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Avid Bioservices shares reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) announced its earnings results on Monday, July, 16th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.15) by $0.20. The biopharmaceutical company earned $6.94 million during the quarter, compared to the consensus estimate of $6.51 million. Avid Bioservices had a negative return on equity of 58.67% and a negative net margin of 40.68%. View Avid Bioservices' Earnings History.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release their next quarterly earnings announcement on Monday, September, 10th 2018. View Earnings Estimates for Avid Bioservices.

What price target have analysts set for CDMO?

5 Wall Street analysts have issued twelve-month target prices for Avid Bioservices' stock. Their forecasts range from $4.00 to $10.00. On average, they anticipate Avid Bioservices' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for Avid Bioservices.

What is the consensus analysts' recommendation for Avid Bioservices?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.

What are Wall Street analysts saying about Avid Bioservices stock?

Here are some recent quotes from research analysts about Avid Bioservices stock:
  • 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (7/19/2018)
  • 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We maintain our Buy rating and are increasing our price target to $6 from $5. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 15x (up from 13x) multiple on F2023 EBITDA discounted back at Avid’s WACC of 13%. Our 15x multiple is based on recent CDMO deals in North America, which ranged from 10-15x for EV/LTM EBITDA." (7/17/2018)

Who are some of Avid Bioservices' key competitors?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the folowing people:
  • Mr. Paul J. Lytle, CFO & Principal Accounting Officer (Age 50)
  • Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Shelley P. M. Fussey Ph.D., VP of Intellectual Property (Age 52)
  • Ms. Tracy L. Kinjerski, VP of Bus. Operations
  • Ms. Lorna Larson, Sr. Director of HR

Has Avid Bioservices been receiving favorable news coverage?

Media headlines about CDMO stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Avid Bioservices earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Avid Bioservices.

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.85%), Renaissance Technologies LLC (0.53%), Bank of New York Mellon Corp (0.23%), Schwab Charles Investment Management Inc. (0.17%), Rhumbline Advisers (0.08%) and Connor Clark & Lunn Investment Management Ltd. (0.05%). View Institutional Ownership Trends for Avid Bioservices.

Which major investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Avid Bioservices.

Which major investors are buying Avid Bioservices stock?

CDMO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Rhumbline Advisers. View Insider Buying and Selling for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $5.57.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $319.70 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-21,810,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 186 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]


MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.